Abstract
Purpose
This review was conducted to examine the current status of paediatric medicines initiatives across the globe.
Methods
The authors made a non-systematic descriptive review of current world situation.
Results
Two regions, the United States (US) and the European Union (EU), and the World Health Organization (WHO) have introduced strong paediatric initiatives to improve children’s health through improving access to better paediatric medicines. The experience from the US initiative indicates that it is possible to stimulate development and study of paediatric medicines and provide important new information for improvement of paediatric therapy. The early results from the EU initiative are similarly encouraging. In Canada, Japan, Australia and other developed countries, specific paediatric medicines initiatives have been less extensive and weaker, with modest results. Disappointingly, current evidence suggests that results from clinical trials outside the US often do not benefit children in the country in which the trials were largely conducted. Pharmaceutical companies that have derived a financial benefit commensurate with the cost of doing the paediatric trials in one country do not seem to be making the results of these trials available to all countries if there is no financial incentive to the company. The WHO campaign ‘make medicines child size’ has produced substantive accomplishments in building improved foundations to improve mechanisms that will enhance children’s access to critical medicines in resource-limited settings. However, practically all of this work has been performed using an amalgamation of short-term funding from a variety of sources as opposed to a sustained, programmatic commitment.
Conclusions
Although much still needs to be done, it’s clear that with concerted efforts and appropriate resources, change is possible but slow. Retaining and fostering public and political interest in paediatric medicines is challenging, but pivotal for success.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoppu K (2008) Paediatric clinical pharmacology: at the beginning of a new era. Eur J Clin Pharmacol 64(2):201–205
World Health Assembly (2007) Resolution WHA60.20 ‘Better medicines for children’
Shirkey H (1968) Therapeutic orphans. J Pediatr 72(1):119–120
Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, Burggraaf J (2007) Stimulation programs for pediatric drug research—do children really benefit? Eur J Pediatr 166(8):849–855. doi:10.1007/s00431-006-0381-z
US FDA (2003) Pediatric Research Equity Act. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf
European Commission (2006) Regulation (EC) no 1901/2006 of the European parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) no 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (2006). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf
Dunne J (2007) The European regulation on medicines for paediatric use. Paediatr Respir Rev 8(2):177–183
Mathis L, Rodriguez W (2009) Drug therapy in pediatrics: a developing field. Dermatol Ther 22(3):257–261. doi:10.1111/j.1529-8019.2009.01239.x
Benjamin DK Jr, Smith PB, Sun MJ, Murphy MD, Avant D, Mathis L, Rodriguez W, Califf RM, Li JS (2009) Safety and transparency of pediatric drug trials. Arch Pediatr Adolesc Med 163(12):1080–1086. doi:10.1001/archpediatrics.2009.229
US FDA Office of Pediatric Therapeutics (2011) Breakdown of FDAAA completed pediatric studies. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm190622.htm. Accessed 20 January 2011
Baker-Smith CM, Benjamin DK Jr, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, Murphy MD, Edwards R, Eisenstein EL, Sun J, Califf RM, Li JS (2008) The economic returns of pediatric clinical trials of antihypertensive drugs. Am Heart J 156(4):682–688. doi:10.1016/j.ahj.2008.05.001
European Medicines Agency (2010) European Medicines Agency receives 1,000th application for a Paediatric Investigation Plan or Waiver. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/10/news_detail_001128.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. Accessed 29 November 2010
European Medicines Agency (2010) Report to the European Commission. http://ec.europa.eu/health/files/paediatrics/article_50_report2010.pdf. Accessed 19 January 2011
Olski TM, Lampus SF, Gherarducci G, Saint Raymond A (2011) Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol 67(3):245–252. doi:10.1007/s00228-011-0997-4
Drug Therapy Committee of the Japan Pediatric Society (2000) Survey of the current state of pediatric drug use in Japan (1994–6). Pediatr Int 42 (1):109–113
Nakamura H, Ozaki M (2010) Facilitation of paediatric research in Japan. In: Rose K, van den Acker JN (eds) Guide to paediatric drug development and clinical research. Karger, Basel, pp 15–22
Department of Health and Ageing (2008) National medicines policy advisory structures and priorities. http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/nmp-advisory-structure.htm. Accessed 6 December 2010
Gazarian M (2009) Delivering better medicines to children: need for better integration between the science, the policy, and the practice. Paediatr Drugs 11(1):41–44
Department of Health and Ageing (2008) Paediatric medicines advisory group. http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/nmp-pmag. Accessed 6 December 2010
Hoppu K, Sri Ranganathan S, Dodoo ANO (2011) Realities of paediatric pharmacotherapy in the developing world. Arch Dis Child. doi:10.1136/adc.2009.180000
Pan American Health Organization (2010) Network for drug regulatory harmonization website. http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=1156&Itemid=513. Accessed 8 December 2010
PANDRH GPC committee (2008) V Pan American conference on drug regulatory harmonization: preliminary report, conclusions and recommendations. http://new.paho.org/hq/dmdocuments/2009/V-Conf-PANDRH_Draft-Reportr.pdf. Accessed 8 December 2010
PANDRH GPC Committee (2008) PANDRH good clinical practices workgroup—draft under discussion—guide for conducting clinical studies in pediatric populations. http://new.paho.org/hq/dmdocuments/2008/VConferencePANDRH_4_ClinicalPractices.pdf. Accessed 8 December 2010
Pan American Health Organization (no year) Guia para realizacion de ensayos clinicos en poblacion pediatrica—borrador en discusion. http://www.anmat.gov.ar/publicaciones/BPC-Investpediatrica.pdf. Accessed 8 December 2010
WHO (2007) WHO global campaign: make medicines child size. http://www.who.int/childmedicines/en/index.html. Accessed 7 January 2011
World Health Organization (2008) The selection and use of essential medicines. Report of the WHO Expert Committee, October 2007 (including the Model List of Essential Medicines for Children). Technical report series, vol 950. WHO, Geneva
World Health Organization (2009) The selection and use of essential medicines. Report of the WHO Expert Committee, 2009 (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List of Essential Medicines for Children), Technical report series, vol 958. WHO, Geneva
Hill S, Gray A, Weber M (2007) Setting standards for essential children's medicines. Bull World Health Organisation 85(9):650
Hoppu K, Hogerzeil HV (2011) Global aspects of drug development. In: Seyberth H, Rane A, Schwab M (eds) Handbook of experimental pharmacology, vol 205. Pediatric clinical pharmacology. Springer, Berlin
WHO (2010) WHO model formulary for children 2010. WHO, Geneva
WHO (2010) Report of WHO second partners meeting on better medicines for children (Geneva, October 2010). http://www.who.int/entity/childmedicines/progress/partners_meeting_2010.pdf. Accessed 7 January 2011
WHO (2008) WHO report of the informal expert meeting on dosage forms of medicines for children. http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf
Ministry of Healthcare and Nutrition and Department of Pharmacology (2006) National list of essential medicines, Sri Lanka, 3rd revision
Ministry of Healthcare and Nutrition and Department of Pharmacology (2009) National list of essential medicines, Sri Lanka, 4th revision
Vitiello B (2008) Recent developments and strategies in pediatric pharmacology research in the USA. Child Adolesc Psychiatry Ment Health 2(1):36. doi:10.1186/1753-2000-2-36
National Institutes of Health (2010) Pediatric trials network. http://bpca.nichd.nih.gov/clinical/network/index.cfm. Accessed 4 December 2010
European Medicines Agency (2011) European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000303.jsp&murl=menus/partners_and_networks/partners_and_networks.jsp&mid=WC0b01ac05801df74a. Accessed 10 January 2011
European Medicines Agency (2011) Enpr-EMA membership. http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/q_and_a/q_and_a_detail_000108.jsp&jsenabled=true. Accessed 10 January 2011
Maternal, Infant, Child and Youth Research Network (MICYRN) (2011) Home page. www.micyrn.ca. Accessed 10 January 2011
Department of Innovation, Industry, Science and Research (2011) Clinical Trials Action Group (CTAG). http://www.innovation.gov.au/Industry/PharmaceuticalsandHealthTechnologies/ClinicalTrialsActionGroup/Pages/default.aspx. Accessed 19 January 2011
US NIH (2010) ClinicalTrials.gov. www.clinicaltrials.gov. Accessed 8 December 2010
Pasquali SK, Burstein DS, Benjamin DK Jr, Smith PB, Li JS (2010) Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics 126:e687–e692. doi:10.1542/peds.2010-0098
Drugs for Neglected Diseases Initiative (2010) Home page. http://www.dndi.org/. Accessed 8 December 2010
TDR (2011) Research on neglected priority needs. http://apps.who.int/tdr/svc/research. Accessed 19 January 2011
Manikandan S, Jayanthi M, Sivagnanam G (2011) Clinical trials in children: an assessment of the information in the Clinical Trials Registry of India (CTRI). Indira Gandhi Medical College & Research Institute, Pondicherry
European Commission, DG Enterprise (2004) Extended impact assessment. http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/paediatrics/docs/extended_impact_assessment_final_3_september_en.pdf. Accessed 19 January 2011
Grieve J, Tordoff J, Reith D, Norris P (2005) Effect of the Pediatric Exclusivity Provision on children's access to medicines. Br J Clin Pharmacol 59(6):730–735
Roberts R, Rodriguez W, Murphy D, Crescenzi T (2003) Pediatric drug labeling. Improving the safety and efficacy of pediatric therapies. JAMA 290(7):905–911
US FDA (2011) Pediatric exclusivity granted. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM223058. Accessed 20 January 2011
Vassal G (2009) Will children with cancer benefit from the new European Paediatric Medicines Regulation? Eur J Cancer 45(9):1535–1546. doi:10.1016/j.ejca.2009.04.008
Leeder JS, Kearns GL, Spielberg SP, van den Anker J (2010) Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 50(12):1377–1387. doi:10.1177/0091270009360533
Yogev R (2005) Balancing the upside and downside of antiretroviral therapy in children. JAMA 293(18):2272–2274. doi:10.1001/jama.293.18.2272
Natu SA, Daga SR (2007) Antiretroviral therapy in children: Indian experience. Indian Pediatr 44(5):339–343
O'Brien DP, Sauvageot D, Zachariah R, Humblet P (2006) In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20(15):1955–1960. doi:10.1097/01.aids.0000247117.66585.ce
WHO/UNAIDS/UNICEF (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. http://www.who.int/hiv/pub/2010progressreport/report/en/index.html%22%20%5Ct%20%22_blank. Accessed 15 November 2010
Acknowledgements
We thank Professor Gita Batmanabane, India, for providing information on the situation in India. Dr Kalle Hoppu and Dr Hidefumi Nakamura are members of the Global Research in Paediatrics (GRIP) consortium which has received research funding from the European Union 7th Framework Program.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoppu, K., Anabwani, G., Garcia-Bournissen, F. et al. The status of paediatric medicines initiatives around the world—what has happened and what has not?. Eur J Clin Pharmacol 68, 1–10 (2012). https://doi.org/10.1007/s00228-011-1089-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1089-1